Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate
Top Cited Papers
Open Access
- 9 January 2003
- journal article
- clinical trial
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 30 (3) , 417-422
- https://doi.org/10.1007/s00259-002-1050-8
Abstract
Medical treatment and chemotherapy are seldom successful in achieving objective tumour reduction in patients with metastatic neuroendocrine tumours. Treatment with the radiolabelled somatostatin analogue [90Y-DOTA0,Tyr3]octreotide may result in partial remissions in 10–25% of patients. The newer analogue [DOTA0,Tyr3]octreotate (octreotate) has a ninefold higher affinity for the somatostatin receptor subtype 2 as compared with [DOTA0,Tyr3]octreotide. Also, labelled with the beta- and gamma-emitting radionuclide 177Lu, it has proved very successful in achieving tumour regression in animal models. The effects of 177Lu-octreotate therapy were studied in 35 patients with neuroendocrine gastro-entero-pancreatic (GEP) tumours who underwent follow-up for 3–6 months after receiving their final dose. Patients were treated with doses of 100, 150 or 200 mCi 177Lu-octreotate, to a final cumulative dose of 600–800 mCi, with treatment intervals of 6–9 weeks. Nausea and vomiting within the first 24 h after administration were present in 30% and 14% of the administrations, respectively. WHO toxicity grade 3 anaemia, leucocytopenia and thrombocytopenia occurred after 0%, 1% and 1% of the administrations, respectively. Serum creatinine and creatinine clearance did not change significantly. The effects of the therapy on tumour size were evaluable in 34 patients. Three months after the final administration, complete remission was found in one patient (3%), partial remission in 12 (35%), stable disease in 14 (41%) and progressive disease in seven (21%), including three patients who died during the treatment period. Tumour response was positively correlated with a high uptake on the octreoscan, limited hepatic tumour mass and a high Karnofsky Performance Score. Because of the limited efficacy of alternative therapies, many physicians currently adopt an expectant attitude when dealing with patients with metastatic GEP tumours. However, in view of the high success rate of therapy with 177Lu-octreotate and the absence of serious side-effects, we advocate its use in patients with GEP tumours without waiting for tumour progression.Keywords
This publication has 14 references indexed in Scilit:
- Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findingsSeminars in Nuclear Medicine, 2002
- Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: The rotterdam experienceSeminars in Nuclear Medicine, 2002
- Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size.2001
- [177Lu-DOTA0,Tyr3]octreotate for somatostatin receptor-targeted radionuclide therapyInternational Journal of Cancer, 2001
- The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumorsAmerican Journal of Gastroenterology, 2000
- Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic useEuropean Journal of Nuclear Medicine and Molecular Imaging, 2000
- In situ radiotherapy with 111In-pentetreotide: initial observations and future directions.1998
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI Journal of the National Cancer Institute, 1993
- Long-Term Management of the Carcinoid Syndrome Treatment with octreotide alone and in combination with alpha-interferonActa Oncologica, 1993
- Gastroenteropancreatic Endocrine Tumours: Effect of Sandostatin® on Tumour GrowthDigestion, 1993